P3 Health Partners Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered officer introductions, voting on four key proposals, and confirmation of quorum. All proposals were approved, with final results to be published in a Form 8-K. No questions were submitted by stockholders.
-
Q1 delivered $26M adjusted EBITDA, exceeding expectations, with revenue up year-over-year despite lower membership. Structural improvements, disciplined execution, and favorable macro trends led to a raised 2026 outlook of $20–$60M adjusted EBITDA.
Fiscal Year 2025
-
Guidance for 2026 targets a $10 million Adjusted EBITDA midpoint, a $170 million improvement year-over-year, driven by contract, operational, and cost structure enhancements. Expansion into a new Medicare Advantage market adds 29,000 members and a multi-year glide path to risk.
-
Q3 results reflect a transitional year with stable medical cost trends, improved provider alignment, and a 6% increase in capitated revenue. Despite a $45.9M adjusted EBITDA loss, operational improvements and contract renegotiations position the business for profitability in 2026.
-
Operating in four states, the organization is focused on value-based care for seniors, leveraging a full-risk model and data-driven platform to drive profitability. Significant EBITDA improvements have been achieved, with further gains targeted for 2026, and membership growth expected to resume after network optimization.
-
Q2 results showed improved operational execution, with normalized EBITDA loss narrowing and medical cost trends flat year-over-year. Revised 2025 guidance reflects prior period headwinds and a single underperforming payer, but significant EBITDA improvement is expected in 2026 from contract, operational, and market changes.
-
Q1 2025 results were in line with expectations, with three of four markets at break-even or better and operational initiatives driving improved efficiency and profitability. Revenue and membership declined year-over-year by design, while per-member funding and medical loss ratio improved. ACO REACH is now profitable and growing.
-
The conference highlighted a $130M+ turnaround plan, operational efficiencies, and technology adoption to drive growth and profitability in 2025 and beyond. Leadership emphasized value-based care, physician engagement, and positive industry tailwinds, with financial forecasts and enrollment updates expected soon.
Fiscal Year 2024
-
Revenue grew 18% year-over-year to $1.5 billion, with membership up 14%. 2025 guidance is reaffirmed for revenue and EBITDA, with profitability expected this year. Operational improvements, contract rationalization, and benefit design changes are driving margin recovery.
-
Q3 2024 saw strong revenue growth and membership gains, but results were impacted by elevated Part B utilization and $35M in retroactive adjustments, leading to a $71M adjusted EBITDA loss. Strategic initiatives and network rationalization are expected to improve profitability and cash flow in 2025.
-
Post-pandemic demand and regulatory changes are driving market volatility and revenue pressure. The business is focused on deepening provider relationships, operational efficiencies, and technology upgrades, aiming for improved margins and cash flow positivity by late 2025.
-
Q2 2024 saw 15% revenue growth and a 50% improvement in Adjusted EBITDA loss, driven by member growth, medical cost reductions, and operational efficiencies. Guidance for 2024 is reiterated, supported by strong cash position and ongoing cost initiatives.
-
Leadership highlighted strong experience in value-based care and outlined a strategy focused on deepening market penetration, operational efficiency, and technology partnerships. Financials show robust revenue and margin growth, with significant upside from improved coding and care management.
-
The presentation highlighted robust membership and revenue growth, operational efficiencies, and a strong value-based care model. Strategic initiatives include deeper market penetration, enhanced analytics partnerships, and disciplined execution to unlock significant EBITDA potential.